Injectable dermal fillers don’t just fill in – they lift too, new study finds


April 28, 2021 – Injectable skin fillers offer a minimally invasive approach to reduce fine lines and wrinkles on the face while restoring facial volume and fullness. Over 2.7 million dermal filler procedures were performed in 2019, according to the most recent statistics of American Society of Plastic Surgeons (ASPS).

Even as the popularity of dermal fillers continues to soar, plastic surgeons are still looking to maximize their benefits for patients seeking non-surgical facial rejuvenation. Most studies used subjective scoring systems, with little objective evidence of the results obtained.

A recent study suggested that in addition to their “volumizing” effects, dermal fillers may also have varying “lifting” effects.. Sebastian Cotofana, MD, PhD, of the Mayo Clinic, Rochester, Minnesota, and colleagues designed a study to measure the true lifting effect of soft tissue fillers in different areas of the face. Their study appears in the May issue of Plastic and Reconstructive Surgery®, the official medical journal of the ASPS.

In the experimental study, the researchers performed standardized injections of skin filler in specially prepared facial cadaver specimens. The injections were given to areas commonly targeted in minimally invasive facial rejuvenation procedures: the forehead and temple; the medial face region, comprising both the medial (central) and lateral (sides) areas; and the perioral area (mouth and chin) and jaw.

To measure the effects of the injections, Dr Cotofana and his colleagues performed before and after scans of the facial surface using advanced three-dimensional scanning technology (Vectra 3D imaging system). The same type of 3D digital imaging system is now commonly used to assess and even simulate the results of plastic and reconstructive surgery procedures.

Scans performed after skin filler injections showed significant increases in local soft tissue volume in the central areas of the face. This was consistent with the well-established clinical effects of “injectable” therapy in the medial regions of the forehead, mid-face, and mouth and chin.

Central facial injections have also shown local lifting effects, including up to a millimeter of vertical “lifting” in the forehead area. However, there was no accompanying regional lifting effect – for example, forehead injection produced no lifting effect in the central areas of the middle or lower face.

Injections in the lateral areas of the face such as the temple, middle of the face and jaw also produced local volume and lifting effects. In addition, the side facial injections created “additional regional lifting effects” in the surrounding areas of the face. For example, the injection into the temple had a slight but significant lifting effect on the lateral medial aspect and jaw.

The combined injection techniques have provided even greater benefits. Added to deep fill injection, a superficial temple injection technique produced an additional 17.5% increase in temple lifting effect, plus a 100% increase in lifting effect of the jaw.

“These results indicate that lateral facial injections co-influence adjacent lateral facial regions and thus may induce regional lifting effects,” write Dr. Cotofana and his co-authors. The results are consistent with previous knowledge of in-depth facial anatomy: Filler injections can cause a change in the tension of the connective tissue (fascia) under the skin, resulting in “repositioning” of the upper layers of the skin.

In this way, filler injections can provide a small but significant lifting effect in a minimally invasive and repeatable procedure. Of course, the gravity-defying lifting effects don’t come close to the impact of facelift surgery. In addition to confirming the previous results on the lifting effects of facial injectables, the study “also broadens their applicability to the total lateral face … to obtain local and regional lifting effects.”

###

Click here to read “Quantitative Analysis of the Lifting Effect of Facial Soft Tissue Filler Injections”.

DOI: 10.1097 / PRS.0000000000007857

Plastic and Reconstructive Surgery® is published in the Lippincott portfolio by Wolters Kluwer.

About Plastic and reconstructive surgery

For over 70 years, Plastic and reconstructive surgery® (http: // www.prsjournal.com /) has always been the only excellent reference for every specialist who uses plastic surgery techniques or works in collaboration with a plastic surgeon. The official journal of the American Society of Plastic Surgeons, Plastic and reconstructive surgery® brings subscribers up-to-date reports on the latest techniques and monitoring from all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, bone repair burns and cosmetic surgery, as well as news on medico-legal issues.

About ASPS

the American Society of Plastic Surgeons is the largest organization of certified plastic surgeons in the world. Representing more than 7,000 member physicians, the society is recognized as a leading authority and source of information on aesthetic and reconstructive plastic surgery. ASPS comprises over 94 percent of all board certified plastic surgeons in the United States. Founded in 1931, the company represents physicians certified by the American Board of Plastic Surgery or the Royal College of Physicians and Surgeons of Canada.

About Wolters Kluwer

Wolters Kluwer (WKL) is a global leader in professional information, software solutions and services for clinicians, nurses, accountants, lawyers and the tax, finance, audit, risk industries. , compliance and regulation. We help our clients make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer achieved 2020 annual sales of 4.6 billion euros. The group serves customers in more than 180 countries, operates in more than 40 countries and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer provides reliable clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision making and outcomes in healthcare. We support clinical efficacy, learning and research, clinical monitoring and compliance, and data solutions. For more information on our solutions, visit https: //www.wolterskluwer.com /Fr /health and follow us on LinkedIn and Twitter @WKHealth.

For more information visit http: // www.wolterskluwer.com, Follow us on Twitter, Facebook, LinkedIn, and Youtube.

Previous Saudis in talks to sell Aramco stake to global energy company
Next Home stay economy stocks may see changes